Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Increased dosing of blinatumomab in children and adolescents with Relapsed/Refractory B-lineage acute lymphoblastic leukemia – beneficial safety profile with 30µg/m²/day in a single center study

View Full Paper
Ask AI
Bookmark
Share

Authors

LGLiana GahleitnerCBChristian BraunCKChristoph Klein

Discussion

Loading...

Member takes

Overview

Retrospective analysis finds 30µg/m²/day blinatumomab safe with similar toxicity and MRD responses in pediatric B-ALL.

Key Points

  • High-dose blinatumomab demonstrated comparable efficacy with standard dosing in pediatric B-ALL.
  • Overall toxicity levels were similar between dosing groups, with no increased CRS severity noted.
  • Retrospective analysis of 18 pediatric patients assessed treatment safety, toxicities, and MRD reductions.
  • Findings suggest potential for dose escalation in pediatric regimens, prompting a need for controlled trials.

Cite This Study

Gahleitner et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e4d6https://doi.org/10.1182/blood-2025-6857
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Leukemia Burden Impacts the Efficacy and Toxicity of Blinatumomab in Pediatric B‐Cell Acute Lymphoblastic Leukemia2025
  2. 2Blinatumomab vs. chemotherapy in pediatrics B-cell ALL: A meta-analysis of randomized controlled trials2025
  3. 3Blinatumomab in pediatric B-acute lymphoblastic leukemia2025 · 6 citations
  4. 4Efficacy and safety of blinatumomab as frontline treatment for infant acute lymphoblastic leukemia2025
  5. 5Low-intensity cytoreduction with low-dose cytarabine prior to blinatumomab for pediatric and AYA R/R ALL integrated with multi-omics analysis to discover predictive biomarkers: Initial results from JPLSG-ALL-R19-blin2025